There are already a number of anti-aggregate drugs on the market, but their effects are not easily reversible, which means that patients are at risk of uncontrolled bleeding if injured. And if they have to undergo an operation for their condition, they should stop treatment within one week before the surgery, which increases the risk of developing blood clots. But researchers at Harvard University have created a non-recited, reversible antiplatelet therapy that uses deactivated "attracting" platelets that can be initiated and reversed immediately.
The baits are made from existing human platelets that have been cleansed by centrifugation and detergent while retaining the adhesive proteins on their surfaces. They bind to other cells that naturally occur in the blood stream, but since they are deactivated, they can not initiate the clotting process. So when added to normal human blood, the overall clotting process is essentially diluted, allowing normal healing processes to take place without the risk of excessive clotting.
As An-Lor Papa, the first author of the newspaper, explains, "baits, unlike normal intact platelets, are unable to bind to the wall of the vessel and will probably prevent the ability of normal platelets to associate." moving skaters sliding on the wall of an ice rink, and their high speed does not allow other skaters to reach the wall, thus limiting them from slowing down and grasping it.
The team believes that therapy can play an important role in the treatment of tumors. Platelets are known to bind to cancer cells by protecting them against the body's immune system and thus helping them to form new tumors. But researchers have found that by adding lures together with normal platelets into microfluidic channels, platelets were almost completely prevented from helping the cancer cells invade the wall of the canal, suggesting that they can prevent the formation of new tumors. Papa says it is possible that one day these lures are deployed during chemotherapy to prevent the spread of existing tumors or the formation of new ones.
So far, therapy has only been tested on rabbits and mice, but the team is convinced that the results can be reproduced in humans. The Pope's Laboratory now works to provide a longer duration of blood baits for efficiency gains, and research into whether they can be loaded with medicines to help deliver therapies directly to blood clots and tumors, or even to kill circulating tumor cells in the blood.